Announced Global Collaboration with Novo Nordisk to Develop Oral Small Molecules for Metabolic Diseases with Over $2.2 Billion in Potential Milestone Payments On Track to Select a Next-Generation Oral ...

SEPN is entitled to receive around $2.2 billion from NVO under the new collaboration deal, which aims to develop oral pills for obesity and other diseases.

Septerna, Novo Nordisk partner to discover, develop and commercialize oral small molecule medicines for cardiometabolic ...

CompanyOverview|NYSE:NVO] Despite a double beat in its quarterly earnings on May 7, Novo Nordisk A/S (NYSE: NVO) stock is ...

From 2015 and 2021, almost 30% of deaths among residents and fellows were due to suicide. In other news: Medicare fraud at UnitedHealth; patient fall rates at rehab facilities; and more.

Correctional officers often dictate end-of-life care for incarcerated people who are terminally ill. Most states either don’t have a formal policy or are given leeway — a big concern for families and ...

The weakness in the Magnificent Seven stocks on Thursday limited gains in the broader market. Amazon.com ( AMZN) and Meta Platforms ( META) closed down more than -2%, and Tesla ( TSLA) closed down ...

DURHAM, N.C., May 15, 2025 (GLOBE NEWSWIRE) -- 374Water Inc. (NASDAQ: SCWO) ("374Water") (the "Company"), a global leader in waste destruction technology for the municipal, federal, and industrial ...

A clinical-stage biotech company developing targeted therapeutics for rare neurodevelopmental disorders. The company’s lead ...

Biohaven shares plunged Thursday after the Food and Drug Administration unexpectedly delayed the review date for its rare-disease drug.